Abstract |
Postapproval studies have an essential role in demonstrating that an intervention is effective and well tolerated during use in daily clinical practice. Numerous large observational and registry studies of tetrahydrocannabinol ( THC): cannabidiol (CBD) oromucosal spray have been conducted subsequent to its approval in Europe in 2011. Collectively, these studies provide valuable insight into various aspects of THC:CBD spray during real-world use in patients with multiple sclerosis spasticity, including its long-term effectiveness and tolerability. The Italian Medicines Agency's web-based registry is the largest observational study of THC:CBD oromucosal spray conducted to date, reporting on more than 1600 patients prescribed THC:CBD spray since it was introduced in Italy in 2013, and further supporting its effectiveness and tolerability profile.
|
Authors | Francesco Patti |
Journal | Neurodegenerative disease management
(Neurodegener Dis Manag)
Vol. 9
Issue 2s
Pg. 3-7
(04 2019)
ISSN: 1758-2032 [Electronic] England |
PMID | 30657027
(Publication Type: Journal Article)
|
Chemical References |
- Cannabinoid Receptor Modulators
- Drug Combinations
- Oral Sprays
- Cannabidiol
- Dronabinol
- nabiximols
|
Topics |
- Administration, Mucosal
- Cannabidiol
(administration & dosage, pharmacology)
- Cannabinoid Receptor Modulators
(administration & dosage, pharmacology)
- Dronabinol
(administration & dosage, pharmacology)
- Drug Approval
- Drug Combinations
- Humans
- Italy
- Multiple Sclerosis
(complications, drug therapy)
- Muscle Spasticity
(drug therapy, etiology)
- Observational Studies as Topic
- Oral Sprays
- Pragmatic Clinical Trials as Topic
- Registries
|